<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119052</url>
  </required_header>
  <id_info>
    <org_study_id>ADPKD-liver</org_study_id>
    <nct_id>NCT02119052</nct_id>
  </id_info>
  <brief_title>Effects of Somatostatin on Liver in ADPKD</brief_title>
  <official_title>Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a
      variety of extrarenal manifestations of which polycystic liver disease is most common. The
      investigators aimed to assess the changes over time of liver volume in ADPKD patients and
      whether it is affected by the treatment with the somatostatin analogue, octreotide.

      35 ADPKD patients (14 males) aged 34Â±8 years were randomly assigned to 36 month treatment
      with placebo (n=18) or octreotide (n=17). Clinical and liver parameters at magnetic resonance
      (RM) were evaluated at baseline, study end and after 24 months of drug withdrawal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of somatostatin on liver volume</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>OCTEOTRIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>octeotride 20 mg, intramuscular injection monthly for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline soluction), intramuscular injection monthly for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>octeotride</intervention_name>
    <arm_group_label>OCTEOTRIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of autosomal dominant polycystic kidney and liver disease

          -  glomerular filtration rate greater than 40 ml/min

        Exclusion Criteria:

          -  diabetes mellitus

          -  proteinuria greater than 1 g/24 hours

          -  significant glomerular disease

          -  urinary tract lithiasis and infections

          -  symptomatic gallstones

          -  biliary sludge

          -  cancer

          -  pregnant women

          -  lactanting women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 18, 2014</last_update_submitted>
  <last_update_submitted_qc>April 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Eleonora Riccio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

